TABLE 2.

Summary of patients who received at least three days of nebulized colistin (COL) for pneumonia

Patient	MBL*	Age, years	Site of care	Susceptibility profile of organism	Days on COL, n	COL base equivalent		Microbiological Outcome	eradication
						Regimen	mg/kg/day†
1	Yes	49	ICU	Not available	10.0	150 mg bid	4.3	F, home	Yes
2	Yes	43	ICU	Not available	20.0	75 mg q8h	3.1	F, home	Yes
3	Yes	68	ICU	S: COL R: PIP, TZP, AG, CIP	16.5	150 mg bid	4.2	F, home	No
4	NC	48	ICU	S: PIP, CAZ, AG R: CIP	6.5	150 mg bid	5.1	F, home	Yes
5	Yes	37	ONC	S: PIP, TZP, AZT, COL R: AG, CIP; I: CAZ	6.7	50 mg tid	2.5	U, home	Yes
6	NC	51	ONC ICU	Not available	13.1	150 mg bid	4.2	F, home	Yes
7	Yes	54	ICU	S: COL R: PIP, CAZ, AZT, AG, CIP	22.5	150 mg bid	7.8	Ind, died	No
8	Yes	59	ICU	Not available	16.8	150 mg bid	3.3	F, home	Yes
9	No	60	GEN	Not available	59.1	150 mg bid	6.0	Ind, home	No
10	No	44	GEN	S: AG, CIP, COL; I: FEP R: TZP, CAZ, AZT	3.6	80 mg bid	3.7	U, home	Yes
11	Yes	64	ICU GEN	See Table 1	4.9	75 mg q8h	3.5	F, home	Yes
12	Yes	46	ICU	See Table 1	25.2	150 mg bid	3.6	F, home	Yes

^*Metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa (resistant to imipenem and meropenem). Isolates 4 and 6 were obtained before 2002, and were not confirmed with EDTA testing. The most frequently encountered minimum inhibitory concentrations were as follows – piperacillin (PIP) 32 μg/mL (susceptible [S]), PIP/tazobactam (TZP) 16 μg/mL (S), ceftazidime (CAZ) 32 μg/mL (resistant [R]), cefipime (FEP) 16 μg/mL (intermediate [I]), aztreonam (AZT) 8 μg/mL (S), gentamicin greater than 128 μg/mL (R), tobramycin greater than 128 μg/mL (R), amikacin 64 μg/mL (R), ciprofloxacin (CIP) 64 μg/mL (R);

^†Using ideal/lean body weight. AG Aminoglycosides; bid Twice a day; F Favourable; GEN General ward; Home Discharged home; ICU Intensive care unit; Ind Indeterminate; NC Not confirmed; ONC Hematology/stem cell transplant unit; q Every; tid Three times a day; U Unfavourable